Romero M, Franzosi M G
Medicina (Firenze). 1989 Jan-Mar;9(1):93-6.
Nizatidine is a new H2-receptor antagonist, as potent as ranitidine. It does not interfere with hepatic metabolism and it lacks anti-androgenic effects. An evening dose of 300 mg suppresses nocturnal acid secretion without diurnal carryover. Published clinical trials are limited. Over 3800 patients who have been treated with nizatidine, 300 mg for up to eight weeks or 150 mg at night for a year, did not appear to have significantly unexpected or unwanted side effects. Rate of healing for both duodenal and gastric ulcers and reduction in the rate of relapse are comparable to those of ranitidine.
尼扎替丁是一种新型H2受体拮抗剂,其效力与雷尼替丁相当。它不干扰肝脏代谢,也没有抗雄激素作用。每晚服用300毫克可抑制夜间胃酸分泌,且无日间残留效应。已发表的临床试验有限。超过3800名患者接受了尼扎替丁治疗,服用300毫克长达8周或每晚服用150毫克长达1年,似乎没有出现明显意外或不良的副作用。十二指肠溃疡和胃溃疡的愈合率以及复发率的降低与雷尼替丁相当。